期刊
CLINICAL INFECTIOUS DISEASES
卷 56, 期 4, 页码 471-477出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis926
关键词
ventilator-associated complication; ventilator-associated pneumonia; surveillance; intensive care unit; hospital-acquired infection
资金
- AstraZeneca
- Novartis
- Johnson Johnson
Background. Hospitals and quality improvement agencies are vigorously focusing on reducing rates of hospital-acquired infection. Ventilator-associated pneumonia (VAP) is notoriously difficult to diagnose and surveillance is thwarted by the subjectivity of many components of the surveillance definition. Alternative surveillance strategies are needed. Ventilator-associated complications (VAC) is a simple, objective measure of respiratory deterioration. Methods. VAC is defined by increases in fraction of inspired oxygen (FiO(2)) by >= 15% or positive end-expiratory pressure (PEEP) by >= 2.5 cm H2O lasting >= 2 days after stable or decreasing FiO(2) or PEEP lasting >= 2 days. We retrospectively assessed patients on mechanical ventilation for >= 48 hours in our study intensive care unit (ICU) using electronic medical record data. We analyzed the association between VAC and clinical diagnoses, ICU length of stay, duration of mechanical ventilation, antibiotic use, and mortality. Results. We assessed 153 patients with VAC and 390 without VAC. VAC events were associated with significantly increased ICU length of stay, duration of mechanical ventilation, and consumption of broad-spectrum antibiotics but not with longer hospital stays or ICU mortality. Conclusions. Surveillance for VAP is subjective and labor intensive. VAC is an objective measure which can be readily obtained from electronic records. It is associated with adverse outcomes and increased broad-spectrum antibiotic usage. VAC may be a useful surveillance tool. The utility of VAC prevention bundles merits assessment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据